

# A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Astria Therapeutics, Inc.
Enrollment	145 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Documented diagnosis of HAE (Type 1 or 2). The following must be met:
- Documented clinical history consistent with HAE
- Lab findings consistent with HAE Type 1 or 2
- Experienced at least 2 HAE attacks during the Run-In period, as confirmed by an investigator based on meeting the protocol-specified definition of an HAE attack.

### Exclusion (7)

- Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathic angioedema, or angioedema associated with urticaria.
- Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to washout prior to entering the Run-In Period).
- Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3 days prior to Run-In
- Plasma-derived C1INH for LTP within 14 days prior to Run-In
- Berotralstat within 21 days prior to Run-In

... and 2 more (see full listing online)

## Locations (79 total)

---

Site 9, Birmingham, Alabama, United States  
Site 2, Scottsdale, Arizona, United States  
Site 3, Little Rock, Arkansas, United States  
... and 76 more locations